Who owns Protagonist Therapeutics (PTGX)? Superinvestor holders

3 superinvestors of the 157 tracked here hold Protagonist Therapeutics (PTGX) in their latest 13F filing, with $935.6M between them. Andrew Spokes gives it the most weight: 4.73% of the reported portfolio. In their latest reported quarter, Andrew Spokes and Stanley Druckenmiller added; Polen Capital team reduced.

Ken Griffin sold out of it in their latest quarter.

Hold it now
3
of 157 tracked
Combined value
$935.6M
Bought / sold
2 / 2
last quarter

Key facts

Superinvestors holding it
3 of 157
Biggest holder
Andrew Spokes, $907M
Largest weight
Andrew Spokes, 4.73%of their portfolio
Combined value
$935.6M
Bought last quarter
2
Sold last quarter
2

From each investor's latest 13F filing: 92 investors report Q3 2026, 65 investors report Q2 2026. Latest filing in this set: Nov 16, 2026.

Superinvestors holding PTGX, latest filings
#InvestorShare of their portfolioValueSharesLast quarterShares movedQuarter
1Andrew SpokesFarallon Capital Management4.73%$907M6.44M▲ Added 1.4%+88.89KQ3 2026
2Stanley DruckenmillerDuquesne Family Office0.59%$25.6M208.9K▲ Added 31%+49.2KQ2 2026
3Polen Capital teamPolen Capital Management0.03%$3M20.96K▼ Reduced 7.5%−1.69KQ3 2026

Sold out last quarter

Quarter by quarter

Superinvestor ownership of PTGX by quarter
QuarterFilings inHoldersCombined sharesCombined valueBoughtSold
Q3 20269226.46M$910M11
Q2 202615736.58M$806.6M13
Q1 202615736.53M$688.6M21
Q4 202515746.42M$561.1M21
Q3 202515736.38M$423.6M30
Q2 202515716.17M$341.1M10
Q1 202515616.11M$295.3M10
Q4 202415615.93M$228.9M10

A quarter's holder count is out of the filings in for that quarter — the newest quarter fills up over the 45 days investors have to file.

Each holder's shares

Shares of PTGX held by each superinvestor, by quarter
InvestorQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024
Andrew Spokes6.44M6.35M6.35M6.14M6.2M6.17M6.11M5.93M
Polen Capital team20.96K22.65K24.34K20.35K20.33K———
Stanley Druckenmiller·208.9K159.7K159.7K159.7K———
George Soros———100K————

A dash: the investor filed for that quarter without this stock among their largest positions. A dot: no filing of theirs for that quarter is on file.

Questions and answers

Which superinvestors own PTGX?

In their latest 13F filings: Andrew Spokes (4.73% of the portfolio, $907M), Stanley Druckenmiller (0.59% of the portfolio, $25.6M), Polen Capital team (0.03% of the portfolio, $3M).

Who bought PTGX last quarter?

Andrew Spokes (added 1.4%), Stanley Druckenmiller (added 31%). “Last quarter” is each investor's latest reported quarter.

Who sold PTGX last quarter?

Reduced: Polen Capital team (7.5% fewer shares). Sold out entirely: Ken Griffin (was $163.6M).

How current is this?

It comes from Form 13F, which large managers file within 45 days of each quarter's end; the latest filing read here was made on Nov 16, 2026. Positions may have changed since, and a 13F shows long US-listed positions only.

Learn

Cite this page

Funkfolio, “Who owns Protagonist Therapeutics (PTGX)? Superinvestor holders”, data as of 16 November 2026. https://funkfolio.com/stock/PTGX/superinvestors

Underlying data: SEC EDGAR, Form 13F-HR filings of the investors tracked here.

Source: SEC EDGAR, Form 13F-HR filings of the 157 investors tracked here, matched to PTGX by security number and name. Only each investor's 150 largest positions per filing are read, so a small line in a very long portfolio is not seen, and a security held without a matched ticker cannot be found. “Last quarter” compares share counts with the investor's previous filing. Share counts are restated for a split only where a tracked investor held the stock through it. Filings appear up to 45 days after a quarter ends and show long US-listed positions only; this is not advice.